Advice
following an abbreviated resubmission:
tiotropium (Spiriva Respimat®) is accepted for use within NHS Scotland.
Indication under review: as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
Tiotropium (Spiriva Respimat®) was previously accepted for restricted use in patients who have poor manual dexterity and therefore have difficulty using the HandiHaler device. Since tiotropium (Spiriva) Respimat is now available at no additional cost compared with tiotropium (Spiriva) HandiHaler the restriction has been removed.
Download detailed advice195KB (PDF)
Medicine details
- Medicine name:
- tiotropium (Spiriva Respimat)
- SMC ID:
- 411/07
- Indication:
- As a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 December 2017